1.888.321.7828 sales@pepid.com

The U.S. FDA approved the first of its kind targeted RNA-based therapy Onpattro (patisiran) to treat peripheral nerve disease (polyneuropathy) caused from hereditary transthyretin-mediated amyloidosis (hATTR) in adult patients. This is the first FDA approved treatment in a new class of drugs called small interfering ribonucleic acid (siRNA) treatment. Read more here.

Share This